CSI Market
Sign In | Register

Aptevo Therapeutics Inc (APVO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access APVO Annual Cash Flow →
Reviewing cash flow figures over time highlights how Aptevo Therapeutics Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-26.20
Depreciation & amortization0.07
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.24
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Income Tax Expense Benefit-
Restricted Cash-
Increase Decrease In Assets And Liabilities Held For Sale-
Increase Decrease In Due To Counterparty-
Impairment Of Goodwill And I Itangible Assets-
Non Cash Interest Expense And Other-
Increase Decrease In Sales Rebates And Discounts-
Increase Decrease In Assets And Liabilities Held For Sale And Amount Due To Counterparty-
Operating Lease Right Of Use Asset Amortization Expense0.27
Increase Decrease In Operating Lease Liability-0.34
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.29
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-1.15
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.46
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities13.80
Discontinued operations0.00
Net Cash flow from Operating Activities-13.42
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Divestiture Of Businesses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.60
Proceeds from Contributions from Parent0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Contingent Consideration Payments-
Proceeds From Payment For Former Parent Upon Spin Off Net Of Receivable-
Payments For Taxes Related To Net Share Settlement Of Equity Awards-
Proceeds From Former Parent-
Settlement Of Contribution Receivable From Former Parent-
Payment Of Tax Liability For Vsted Equity Awards-
Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net-
Proceeds From Exercise Of Pre Funded Warrants-
Payment Of Tax Liability For Vested Equity Awards-
Proceeds From Long Term Debt Net Of Issuance Costs And Modification Fees-
Proceeds From Sale Of Future Royalties-
Transaction Costs From Sale Of Future Royalties-
Repayments Under Liability Related To Sale Of Royalties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.60
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-13.42
Total Cash Flow-11.82
4 historic quarters locked

Sign in to unlock the full Aptevo Therapeutics Inc cash flow history.

Sign In Create Free Account

About Aptevo Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-350559

Figures are derived from filed reports and may be restated. Historical data is subject to revision.